Evaluation of the efficacy of molecular targeted drugs using biopsy samples in patients with advanced hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000039887
- Lead Sponsor
- Department of Gastroenterology and Metabolism, Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with allergy to lenvatinib, sorafenib, bevacizumab, atezolizumab, local anesthetics, or analgesics Patients with severe ascites, severe renal failure, severe anemia, severe thrombocytopenia, jaundice, or coagulation disorder Patients who need to take anticoagulants or anti-platelet drugs continuously Patients with severe cognitive dysfunction or psychiatric disorders Patients with severe heart failure Pregnant or nursing mothers, woman who desire to bear children
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histological treatment effects obtained four weeks after the start of molecular targeted drugs
- Secondary Outcome Measures
Name Time Method